Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †

During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer an...

Full description

Bibliographic Details
Main Authors:	Mlakar, Vid, Huezo-Diaz Curtis, Patricia, Satyanarayana Uppugunduri, Chakradhara Rao, Krajinovic, Maja, Ansari, Marc
Format:	Online
Language:	English
Published:	MDPI 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037779/

id	pubmed-5037779
recordtype	oai_dc
spelling	pubmed-50377792016-09-29 Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use † Mlakar, Vid Huezo-Diaz Curtis, Patricia Satyanarayana Uppugunduri, Chakradhara Rao Krajinovic, Maja Ansari, Marc Review During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer and harmonization of pharmacogenetic testing from research into clinics, to bring together basic and translational research and to educate health professionals throughout Europe. The objective of this review was to provide the attendees of the meeting as well as the larger scientific community an insight into the compiled evidence regarding current pharmacogenomics knowledge in pediatric oncology. This preliminary evaluation will help steer the committee’s work and should give the reader an idea at which stage researchers and clinicians are, in terms of personalizing medicine for children with cancer. From the evidence presented here, future recommendations to achieve this goal will also be suggested. MDPI 2016-09-08 /pmc/articles/PMC5037779/ /pubmed/27618021 http://dx.doi.org/10.3390/ijms17091502 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Mlakar, Vid Huezo-Diaz Curtis, Patricia Satyanarayana Uppugunduri, Chakradhara Rao Krajinovic, Maja Ansari, Marc
spellingShingle	Mlakar, Vid Huezo-Diaz Curtis, Patricia Satyanarayana Uppugunduri, Chakradhara Rao Krajinovic, Maja Ansari, Marc Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
author_facet	Mlakar, Vid Huezo-Diaz Curtis, Patricia Satyanarayana Uppugunduri, Chakradhara Rao Krajinovic, Maja Ansari, Marc
author_sort	Mlakar, Vid
title	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
title_short	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
title_full	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
title_fullStr	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
title_full_unstemmed	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
title_sort	pharmacogenomics in pediatric oncology: review of gene—drug associations for clinical use †
description	During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer and harmonization of pharmacogenetic testing from research into clinics, to bring together basic and translational research and to educate health professionals throughout Europe. The objective of this review was to provide the attendees of the meeting as well as the larger scientific community an insight into the compiled evidence regarding current pharmacogenomics knowledge in pediatric oncology. This preliminary evaluation will help steer the committee’s work and should give the reader an idea at which stage researchers and clinicians are, in terms of personalizing medicine for children with cancer. From the evidence presented here, future recommendations to achieve this goal will also be suggested.
publisher	MDPI
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037779/
_version_	1613662109893132288

Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †

Similar Items